Ongoing phase I/II clinical trials (NCT03170206 and NCT02022982) in advanced KRAS-driven NSCLC patients are investigating the combinatorial effect of MEK and CDK4 inhibitors. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.